• Clinical Insights: August 18, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or… Read more »

  • Clinical Insights: August 11, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New… Read more »

  • Join Us at the 2017 NACHC – CHI & EXPO!

    August 25-29, 2017, the RxStrategies team, including, Rhodie Smith (Vice President of Contract Pharmacy Sales) and Jordan Hytken (Senior Account Executive), will be connecting with industry leaders at the National Association of Community Health Centers (NACHC) Community Health Institute (CHI) & EXPO in San Diego, California. Get more event details here > Visit Booth #208… Read more »

  • Clinical Insights: August 4, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vyxeos™ (cytarabine and daunorubicin) – August 3, 2017 – The U.S. Food and Drug Administration approved Vyxeos™ for the treatment of adults with two types of acute… Read more »

  • Clinical Insights: July 28, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) – July 18, 2017 – The U.S. Food and Drug Administration approved Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without… Read more »

  • Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • CEO Fenton Markevich on the Importance of 340B

    President and CEO Fenton Markevich was recently featured in 340B Health’s 340B Chronicle, News from the 340B Health PAC. In this highlight, Fenton answered questions pertaining to his personal commitment and RxStrategies’ commitment to the 340B community and the 340B program, as well as the significance of contributing to the 340B Health PAC. Read the… Read more »

  • Clinical Insights: July 7, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Endari™ (L-glutamine oral powder) – July 7, 2017 – The U.S. Food and Drug Administration approved Endari (L-glutamine oral powder) for patients age five years and older… Read more »

  • Ready to Connect at the 340B Coalition Summer Conference!

    RxStrategies is proud to be a Pinnacle Leader Sponsor of the 2017 340B Coalition Summer Conference, July 10-12. Our team will be connecting with industry leaders to gain insight and discuss the latest 340B Program developments during this highly attended conference. RxStrategies’ 340BPlus™ CompliancePlus (Self-Audit Tool), Dashboard Analytics, Contract Pharmacy, Split Billing and Specialty Pharmacy solutions are key to a… Read more »

  • Clinical Insights: June 30, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New… Read more »